Wachters FM - Search Results

1

Genetic factors influencing pyrimidine-antagonist chemotherapy.

Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG. Maring JG, et al. Among authors: wachters fm. Pharmacogenomics J. 2005;5(4):226-43. doi: 10.1038/sj.tpj.6500320. Pharmacogenomics J. 2005. PMID: 16041392 Review.

2

Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.

Maring JG, Wachters FM, Slijfer M, Maurer JM, Boezen HM, Uges DR, de Vries EG, Groen HJ. Maring JG, et al. Among authors: wachters fm. Eur J Clin Pharmacol. 2010 Jun;66(6):611-7. doi: 10.1007/s00228-010-0799-0. Epub 2010 Mar 6. Eur J Clin Pharmacol. 2010. PMID: 20213492 Free PMC article. Clinical Trial.

3

Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer.

Maring JG, Wachters FM, Maurer M, Uges DR, de Vries EG, Groen HJ. Maring JG, et al. Among authors: wachters fm. Ther Drug Monit. 2010 Jun;32(3):364-8. doi: 10.1097/FTD.0b013e3181d631a6. Ther Drug Monit. 2010. PMID: 20335827

4

Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study.

Stokman MA, Wachters FM, Koopmans P, Burgerhof JG, Groen HJ, Spijkervet FK, Uges DR, Hospers GA. Stokman MA, et al. Among authors: wachters fm. Anticancer Res. 2004 Sep-Oct;24(5B):3263-7. Anticancer Res. 2004. PMID: 15510621 Free article. Clinical Trial.

5

ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy.

Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. Wachters FM, et al. Lung Cancer. 2005 Nov;50(2):211-9. doi: 10.1016/j.lungcan.2005.06.013. Epub 2005 Sep 16. Lung Cancer. 2005. PMID: 16169122

6

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.

Wachters FM, Groen HJ, Maring JG, Gietema JA, Porro M, Dumez H, de Vries EG, van Oosterom AT. Wachters FM, et al. Br J Cancer. 2004 Jun 14;90(12):2261-7. doi: 10.1038/sj.bjc.6601811. Br J Cancer. 2004. PMID: 15150611 Free PMC article. Clinical Trial.

7

Selective targeting of homologous DNA recombination repair by gemcitabine.

Wachters FM, van Putten JW, Maring JG, Zdzienicka MZ, Groen HJ, Kampinga HH. Wachters FM, et al. Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):553-62. doi: 10.1016/s0360-3016(03)00503-0. Int J Radiat Oncol Biol Phys. 2003. PMID: 12957269

8

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.

Wachters FM, Van Putten JW, Kramer H, Erjavec Z, Eppinga P, Strijbos JH, de Leede GP, Boezen HM, de Vries EG, Groen HJ. Wachters FM, et al. Br J Cancer. 2003 Oct 6;89(7):1192-9. doi: 10.1038/sj.bjc.6601283. Br J Cancer. 2003. PMID: 14520444 Free PMC article. Clinical Trial.

9

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.

Wachters FM, Groen HJ, Biesma B, Schramel FM, Postmus PE, Stigt JA, Smit EF. Wachters FM, et al. Br J Cancer. 2005 Jan 17;92(1):15-20. doi: 10.1038/sj.bjc.6602268. Br J Cancer. 2005. PMID: 15597104 Free PMC article. Clinical Trial.

10

Determination of epirubicin and its metabolite epirubicinol in saliva and plasma by HPLC.

Dodde WI, Maring JG, Hendriks G, Wachters FM, Groen HJ, de Vries EG, Uges DR. Dodde WI, et al. Among authors: wachters fm. Ther Drug Monit. 2003 Aug;25(4):433-40. doi: 10.1097/00007691-200308000-00003. Ther Drug Monit. 2003. PMID: 12883225

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters